David Noble to leave Edelman

David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure.

Noble has been heading the agency's specialist medical communications business unit for more than three years. He is to leave this month following a three-week consultation process.

Steve Spurr who leads Edleman's ethical healthcare division will take over Noble's responsibilities.

Robert Phillips, Edelman UK CEO told PR Week: "The BioScience and Rx divisions will remain separate, but will be headed by Steve. We are reorganising internally to have more fluent interaction between the teams."

The BioScience division specialises in advisory board management, clinical trial recruitment/retention, market access support, publication planning, meetings and symposia.